The Latest Breaking News from FDA

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

Neffy, the first single-dose nasal spray approved to treat severe allergies, will hit the market in a matter of weeks

Blue-chip dividend stocks are of well-established companies offering steady income and financial stability. They are ideal for securing a resilient retirement portfolio, combining consistent dividends with potential capital appreciation. Thus, quality blue-chip dividend stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and McDonald’s (MCD) could be ideal portfolio additions for retirement…

The FDA, which approved the protocols for the studies it now questions, is asking for an additional Phase 3 clinical trial, which would take years and millions of dollars.

The Food and Drug Administration declined to approve MDMA as the first psychedelic drug used to treat post-traumatic stress disorder.

The new treatment, a needle-free alternative, could be used for managing severe allergic responses in children and adults, weighing at least 66 pounds, the FDA said.

JD Vance supports state autonomy in abortion policy, advocating for varied regulations based on state decisions.

FDA approves Neffy, a needle-free nasal spray epinephrine for anaphylaxis treatment, providing a convenient and effective option for severe allergic reactions.

FDA declines approval for MDMA as PTSD treatment, citing safety and efficacy concerns. Further trials needed.